Drug:
Reaction: PRODUCT USE ISSUE
20250101 - 20251231
No. 501 - 600
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 501 | 25077558 |
US |
69 | 2 |
Product use issue, Intentional product misuse, |
||||
| 502 | 25077598 |
CA |
2 | |
Acute respiratory distress syndrome, Amnesia, Asthenia, Brain fog, Condition aggravated, Injection site granuloma, Multiple organ dysfunction syndrome, Pulmonary hypertension, Weight decreased, Fatigue, Malaise, Acute kidney injury, Cardiac disorder, Nausea, Diarrhoea, Vomiting, Dizziness, Off label use, Product use issue, |
||||
LANREOTIDE ACETATE, LANREOTIDE ACETATE, DROSPIRENONE AND ESTRADIOL, CARVEDILOL, CHLORTHALIDONE, CYANOCOBALAMIN, CYCLOBENZAPRINE, ESOMEPRAZOLE SODIUM, FLUOXETINE HYDROCHLORIDE, FLUOXETINE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, FERRIC DERISOMALTOSE, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN, ALBUTEROL SULFATE, ALBUTEROL, THIAMINE HYDROCHLORIDE, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, |
||||
| 503 | 25077714 |
US |
||
No adverse event, Product availability issue, Product use issue, |
||||
LISDEXAMFETAMINE DIMESYLATE, |
||||
| 504 | 25077728 |
US |
66 | 2 |
Product use issue, Product dispensing error, |
||||
LENALIDOMIDE, |
||||
| 505 | 25077816 |
US |
58 | 2 |
Cataract operation, Product container issue, Product leakage, Product use issue, Product container seal issue, Poor quality product administered, Patient dissatisfaction with treatment, Product complaint, Wrong technique in product usage process, Circumstance or information capable of leading to medication error, Product knowledge deficit, |
||||
PERFLUOROHEXYLOCTANE, |
||||
| 506 | 25077831 |
CA |
31 | 2 |
Brain fog, Crohn^s disease, Eye discharge, Vision blurred, Fatigue, Rash pruritic, Rash, Therapeutic response shortened, Product use issue, |
||||
ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, COLESTIPOL HYDROCHLORIDE, FLUTICASONE PROPIONATE, ALBUTEROL SULFATE, |
||||
| 507 | 25077916 |
BE |
14 | 2 |
Abdominal pain, Vomiting, Intentional overdose, Product use issue, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 508 | 25078089 |
BE |
23 | 2 |
Hepatic failure, Intentional overdose, Product use issue, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 509 | 25078107 |
BE |
13 | 1 |
Malaise, Abdominal pain upper, Intentional overdose, Product use issue, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 510 | 25078109 |
US |
70 | 2 |
Headache, Migraine, Product use issue, |
||||
FREMANEZUMAB-VFRM, FREMANEZUMAB-VFRM, |
||||
| 511 | 25078173 |
US |
1 | |
Product use issue, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 512 | 25078211 |
CA |
50 | 2 |
Abdominal discomfort, Abdominal pain upper, Anti-cyclic citrullinated peptide antibody positive, Asthenia, C-reactive protein abnormal, Condition aggravated, Contraindicated product administered, Contusion, Diarrhoea, Dyspnoea, Discomfort, Fibromyalgia, Frequent bowel movements, Hand deformity, Hepatic enzyme increased, Hypersensitivity, Infection, Insomnia, Joint range of motion decreased, Joint swelling, Lip dry, Liver disorder, Lower limb fracture, Lower respiratory tract infection, Lung disorder, Lupus-like syndrome, Malaise, Medication error, Muscle injury, Muscle spasms, Musculoskeletal pain, Musculoskeletal stiffness, Night sweats, Obesity, Oedema, Oedema peripheral, Off label use, Osteoarthritis, Osteoporosis, Pain in extremity, Pancreatitis, Paraesthesia, Peripheral swelling, Peripheral venous disease, Pneumonia, Porphyria acute, Prescribed overdose, Product use in unapproved indication, Product use issue, Pruritus, Psoriatic arthropathy, Pulmonary fibrosis, Pyrexia, Rash, Rectal haemorrhage, Retinitis, Rheumatic fever, Rheumatoid arthritis, Rheumatoid factor positive, Sinusitis, Sleep disorder, Sleep disorder due to general medical condition, insomnia type, Stomatitis, Swelling, Synovitis, Systemic lupus erythematosus, Therapeutic product effect decreased, Therapy non-responder, Treatment failure, Type 2 diabetes mellitus, Urticaria, Weight decreased, Weight fluctuation, Weight increased, Wheezing, Wound, Wound infection, X-ray abnormal, |
||||
RITUXIMAB, RITUXIMAB, RITUXIMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, |
||||
| 513 | 25078463 |
CA |
70 | 2 |
Rectal haemorrhage, Product use issue, Constipation, Underdose, Prescribed underdose, |
||||
RAMIPRIL, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, CALCIUM, ROSUVASTATIN, PREGABALIN, NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE, PANTOPRAZOLE, |
||||
| 514 | 25078823 |
BE |
2 | |
Ataxia, Somnolence, Vertigo, Intentional overdose, Product use issue, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 515 | 25078838 |
US |
||
Product use issue, |
||||
RELUGOLIX, RELUGOLIX, ENZALUTAMIDE, PREGABALIN, ALFUZOSIN HYDROCHLORIDE, AMBRISENTAN, FUROSEMIDE, FUROSEMIDE, METOPROLOL TARTRATE, METOPROLOL, BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE, VALACYCLOVIR, VALACYCLOVIR HYDROCHLORIDE, CLOPIDOGREL, CLOPIDOGREL BISULFATE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, |
||||
| 516 | 25079037 |
US |
1 | |
Hallucination, Product use issue, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 517 | 25079040 |
JP |
||
Product use issue, Wrong technique in product usage process, Product preparation issue, |
||||
MOLNUPIRAVIR, |
||||
| 518 | 25079133 |
US |
86 | 2 |
Product use issue, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 519 | 25079215 |
US |
63 | 2 |
Product use issue, Device delivery system issue, |
||||
FLUTICASONE PROPIONATE AND SALMETEROL, |
||||
| 520 | 25079292 |
US |
70 | 2 |
Off label use, Product use issue, |
||||
ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, DULOXETINE HYDROCHLORIDE, DULOXETINE, CAPECITABINE, ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, GABAPENTIN, FUROSEMIDE, |
||||
| 521 | 25079580 |
US |
52 | 1 |
Product dose omission issue, Product use issue, |
||||
ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE, |
||||
| 522 | 25079691 |
US |
71 | 2 |
Product use issue, |
||||
LENALIDOMIDE, |
||||
| 523 | 25079950 |
US |
70 | 2 |
Tardive dyskinesia, Product use issue, Loss of personal independence in daily activities, |
||||
DEUTETRABENAZINE, |
||||
| 524 | 25080046 |
CA |
2 | |
Exposure during pregnancy, Infusion related reaction, Intentional product misuse, Off label use, Overdose, Pain, Product use issue, Prescribed overdose, |
||||
HYDROMORPHONE HYDROCHLORIDE, MORPHINE SULFATE, MORPHINE SULFATE, STANDARDIZED SENNA CONCENTRATE, SENNOSIDES A AND B, ABACAVIR SULFATE, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, ALBUTEROL SULFATE, ALBUTEROL SULFATE, ALBUTEROL, BUPROPION HYDROCHLORIDE, BUPROPION, BUPROPION HYDROCHLORIDE, BUPROPION, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CLONIDINE, CYCLOBENZAPRINE, MEPERIDINE HYDROCHLORIDE, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE, FLUCONAZOLE, FUROSEMIDE, GABAPENTIN, ADALIMUMAB, ADALIMUMAB, HYDROMORPHONE HYDROCHLORIDE, KETOPROFEN, METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE, MONTELUKAST SODIUM, MONTELUKAST, MONTELUKAST SODIUM, MONTELUKAST, MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, ABATACEPT, ABATACEPT, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, PROGESTERONE, PROGESTERONE, QUETIAPINE FUMARATE, QUETIAPINE, RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE, INFLIXIMAB, TEMAZEPAM, RITUXIMAB, RITUXIMAB, ALBUTEROL SULFATE, ALBUTEROL, SENNA LEAF, SENNA LEAF, TEMAZEPAM, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE, ALBUTEROL SULFATE, VITAMIN C, BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE, |
||||
| 525 | 25080056 |
US |
68 | 2 |
Endometrial cancer recurrent, Anaemia, Cortisol decreased, Blood test abnormal, Hospitalisation, Product use issue, Illness, |
||||
PEMBROLIZUMAB, |
||||
| 526 | 25083540 |
2 | ||
Therapy interrupted, Pain, Product use issue, |
||||
GUSELKUMAB, |
||||
| 527 | 25071655 |
US |
||
Asthma, Product use issue, |
||||
ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 528 | 25071696 |
US |
||
Pulmonary oedema, Dyspnoea, Product use issue, |
||||
| 529 | 25071700 |
HU |
56 | 2 |
Death, Pancytopenia, Febrile neutropenia, Pseudomonas infection, Pneumonia fungal, Product use issue, Off label use, |
||||
GILTERITINIB, CLADRIBINE, CYTARABINE, VENETOCLAX, |
||||
| 530 | 25071796 |
US |
46 | 1 |
Product dose omission issue, Product use issue, |
||||
ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE, |
||||
| 531 | 25071807 |
CA |
61 | 2 |
Aphonia, Arthralgia, Body temperature decreased, Cough, Drug hypersensitivity, Ear infection, Hypoventilation, Limb discomfort, Middle ear effusion, Nasopharyngitis, Off label use, Pneumonia, Product use issue, Productive cough, Rash, Road traffic accident, Sinusitis, Tendonitis, Tissue injury, Weight decreased, Wheezing, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, AMOXICILLIN, MONTELUKAST SODIUM, TIOTROPIUM BROMIDE, |
||||
| 532 | 25071886 |
FR |
11 | 1 |
Hypogammaglobulinaemia, Product use issue, Off label use, |
||||
TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, PREDNISONE, PREDNISONE, PREDNISONE, METHYLPREDNISOLONE, OBINUTUZUMAB, DARATUMUMAB, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 533 | 25071928 |
FR |
12 | 2 |
Osteonecrosis, Skin ulcer, Haemoptysis, Drug ineffective, Chronic kidney disease, Polyomavirus-associated nephropathy, Pneumonia bacterial, Staphylococcal infection, Citrobacter infection, Haemophilus infection, Varicella zoster virus infection, Product use issue, |
||||
TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, PREDNISONE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, METHYLPREDNISOLONE, VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR, VALGANCICLOVIR HYDROCHLORIDE POWDER,, ACYCLOVIR, RUXOLITINIB, RUXOLITINIB, AMPHOTERICIN B, |
||||
| 534 | 25072154 |
US |
||
Product use issue, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 535 | 25072232 |
US |
83 | 1 |
Weight decreased, Product use issue, |
||||
PEGFILGRASTIM, |
||||
| 536 | 25072369 |
US |
50 | 2 |
Product use issue, |
||||
LENALIDOMIDE, |
||||
| 537 | 25072388 |
JP |
56 | 1 |
Immune-mediated hepatitis, Malignant neoplasm progression, Product use issue, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 538 | 25072544 |
CN |
2 | |
Pneumonia, White blood cell count decreased, Platelet count decreased, Lymphocyte count decreased, Product use issue, |
||||
RIBOCICLIB, LETROZOLE, |
||||
| 539 | 25072566 |
CA |
2 | |
Hypotension, Hypertension, Mood altered, Weight decreased, Dizziness, Product use issue, Wrong technique in product usage process, |
||||
SEMAGLUTIDE, |
||||
| 540 | 25072610 |
US |
2 | |
Pregnancy with implant contraceptive, Unintended pregnancy, Incorrect product administration duration, Product use issue, |
||||
ETONOGESTREL, |
||||
| 541 | 25072664 |
FR |
6 | 1 |
Hypogammaglobulinaemia, Product use issue, Off label use, |
||||
TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, DARATUMUMAB, PREDNISONE, PREDNISONE, PREDNISONE, OBINUTUZUMAB, METHYLPREDNISOLONE, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 542 | 25072692 |
US |
||
Fall, Traumatic intracranial haemorrhage, Product use issue, Skull fracture, |
||||
DAPAGLIFLOZIN, |
||||
| 543 | 25072838 |
FR |
9 | 1 |
Hypogammaglobulinaemia, Neutropenia, Urticaria, Product use issue, Off label use, |
||||
TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, PREDNISONE, PREDNISONE, PREDNISONE, DARATUMUMAB, CYCLOSPORINE, OBINUTUZUMAB, METHYLPREDNISOLONE, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 544 | 25073044 |
CA |
76 | 2 |
Pneumonia, Rib fracture, Fatigue, Injection site erythema, Product use issue, |
||||
| 545 | 25073059 |
US |
71 | 2 |
Symptom recurrence, Product use in unapproved indication, Product use issue, |
||||
DEUTETRABENAZINE, |
||||
| 546 | 25073139 |
US |
1 | |
Product use issue, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 547 | 25073190 |
BE |
13 | 2 |
Vomiting, Overdose, Product use issue, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 548 | 25073231 |
US |
||
Product use issue, Withdrawal syndrome, |
||||
LISDEXAMFETAMINE DIMESYLATE, |
||||
| 549 | 25073235 |
US |
1 | |
Product use issue, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 550 | 25073374 |
FR |
11 | 1 |
Hypogammaglobulinaemia, Product use issue, Off label use, |
||||
TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, DARATUMUMAB, OBINUTUZUMAB, PREDNISONE, PREDNISONE, PREDNISONE, METHYLPREDNISOLONE, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 551 | 25073621 |
US |
82 | 2 |
Product use issue, |
||||
APIXABAN, |
||||
| 552 | 25073746 |
US |
1 | |
Drug effect less than expected, Product use issue, |
||||
POLYETHYLENE GLYCOL 3350, |
||||
| 553 | 25073803 |
US |
9 | 2 |
Product use issue, Product use in unapproved indication, |
||||
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350, |
||||
| 554 | 25073878 |
CA |
43 | 2 |
Arthralgia, Blister, Drug hypersensitivity, Drug intolerance, Hepatic enzyme increased, Hypercholesterolaemia, Hypertension, Infusion related reaction, Muscle spasms, Pemphigus, Rheumatoid arthritis, Synovitis, Stomatitis, Systemic lupus erythematosus, Type 2 diabetes mellitus, Urticaria, Wheezing, Wound infection, Contraindicated product administered, Intentional product use issue, Product use in unapproved indication, Product use issue, Off label use, Treatment failure, Therapeutic product effect decreased, Hand deformity, Leukopenia, Hypertransaminasaemia, Maternal exposure during pregnancy, Hypersensitivity, Joint swelling, Oedema, Deep vein thrombosis postoperative, Psoriatic arthropathy, |
||||
RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ERENUMAB-AOOE, ERENUMAB-AOOE, SECUKINUMAB, DICLOFENAC, DICLOFENAC SODIUM, DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, METHOTREXATE SODIUM, METHOTREXATE SODIUM, METHOTREXATE SODIUM, METHOTREXATE SODIUM, METHOTREXATE SODIUM, METHOTREXATE SODIUM, METHOTREXATE SODIUM, METHOTREXATE SODIUM, METHOTREXATE SODIUM, CALCIUM CHLORIDE INJECTION, CALCIUM CHLORIDE, CALCIUM GLUCONATE, CALCIUM GLUCONATE, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CORTISONE ACETATE, CORTISONE ACETATE, CORTISONE ACETATE, DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE TABLETS, GOLIMUMAB, SARILUMAB, PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HCL, TOCILIZUMAB, TOCILIZUMAB, CALCIUM CARBONATE, HYDROCORTISONE ACETATE, LORAZEPAM, CAFFEINE, CALCIUM, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, LANSOPRAZOLE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, LISINOPRIL, LORAZEPAM, MAGNESIUM, MELOXICAM, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, PIROXICAM, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, QUETIAPINE FUMARATE, QUETIAPINE, RAMIPRIL, RISEDRONATE SODIUM, SULFASALAZINE, FISH OIL, ERGOCALCIFEROL, |
||||
| 555 | 25074227 |
US |
2 | |
Product use issue, Therapy interrupted, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 556 | 25074289 |
CA |
||
Abdominal discomfort, Adverse drug reaction, Alopecia, Arthralgia, Anti-cyclic citrullinated peptide antibody positive, Arthritis, Bone erosion, C-reactive protein increased, Condition aggravated, Crohn^s disease, Decreased appetite, Discomfort, Dizziness, Drug hypersensitivity, Drug intolerance, Ear infection, Exostosis, Fatigue, Foot deformity, General physical health deterioration, Glossodynia, Hand deformity, Headache, Hepatic cirrhosis, Hepatic enzyme increased, Hypersensitivity, Hypoaesthesia, Infection, Infusion related reaction, Joint dislocation, Joint stiffness, Joint swelling, Laryngitis, Lupus-like syndrome, Malaise, Mobility decreased, Musculoskeletal stiffness, Nausea, Oedema peripheral, Osteoarthritis, Osteoporosis, Pain, Pain in extremity, Pemphigus, Pericarditis, Pneumonia, Rash, Red blood cell sedimentation rate increased, Retinitis, Rheumatoid arthritis, Rheumatoid factor positive, Synovitis, Systemic lupus erythematosus, Visual impairment, Wound, Exposure during pregnancy, Treatment failure, Contraindicated product administered, Drug ineffective, Therapeutic product effect decreased, Therapeutic product effect incomplete, Incorrect route of product administration, Product use in unapproved indication, Product use issue, Off label use, |
||||
ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, ALENDRONATE SODIUM, ALENDRONATE SODIUM, ALENDRONATE SODIUM, ALENDRONATE SODIUM, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, PREDNISONE, PREDNISONE, PREDNISONE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LORAZEPAM, AZATHIOPRINE, CALCIUM, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CORTISONE ACETATE, CORTISONE ACETATE, CORTISONE ACETATE, CORTISONE ACETATE, CORTISONE ACETATE, CORTISONE ACETATE, CORTISONE ACETATE, CORTISONE ACETATE, CORTISONE ACETATE, CORTISONE ACETATE, CORTISONE ACETATE, CORTISONE ACETATE, CORTISONE ACETATE, CORTISONE ACETATE, CORTISONE ACETATE, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE CAPSULE, LIQUID FILLED, DOXYCYCLINE HYCLATE, DOXYCYCLINE, DOXYCLYCLINE HYCLATE, DOXYCYCLINE HYCLATE, DOXYCYCLINE, DOXYCLYCLINE HYCLATE, ETANERCEPT, ETANERCEPT, ETANERCEPT, ETANERCEPT, ETANERCEPT, ETANERCEPT, ETANERCEPT, ETANERCEPT, ETANERCEPT, ETANERCEPT, ERGOCALCIFEROL, ETANERCEPT, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, ALENDRONATE SODIUM, ALENDRONATE SODIUM, ALENDRONATE SODIUM, ALENDRONATE SODIUM, ALENDRONATE SODIUM, ALENDRONATE SODIUM, GOLIMUMAB, GOLIMUMAB, ADALIMUMAB, ADALIMUMAB, ADALIMUMAB, ADALIMUMAB, ADALIMUMAB, ADALIMUMAB, ADALIMUMAB, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, ADALIMUMAB-ADAZ, ADALIMUMAB-ADAZ, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, SARILUMAB, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE, METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE, METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE, METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE, MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE, MORPHINE SULFATE, ABATACEPT, ABATACEPT, ABATACEPT, APREMILAST, APREMILAST, APREMILAST, APREMILAST, APREMILAST, APREMILAST, APREMILAST, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, HYDROXYCHLOROQUINE SULFATE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HCL, QUETIAPINE FUMARATE, QUETIAPINE, RAMIPRIL, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, SECUKINUMAB, GOLIMUMAB, GOLIMUMAB, GOLIMUMAB, GOLIMUMAB, GOLIMUMAB, GOLIMUMAB, GOLIMUMAB, GOLIMUMAB, USTEKINUMAB, USTEKINUMAB, USTEKINUMAB, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, DESOXIMETASONE, DESOXIMETASONE, CALCIUM CARBONATE, USTEKINUMAB, USTEKINUMAB, USTEKINUMAB, VITAMIN C, VITAMIN C, VITAMIN C, PREDNISONE, BUPROPION HYDROCHLORIDE, BUPROPION, CAFFEINE CITRATE, DICLOFENAC, DICLOFENAC SODIUM, HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, LISINOPRIL, SULFASALAZINE, BUPROPION HYDROCHLORIDE, TOFACITINIB, |
||||
| 557 | 25074357 |
US |
2 | |
Product use issue, Dysarthria, Depression, Insomnia, |
||||
DIROXIMEL FUMARATE, DIROXIMEL FUMARATE, |
||||
| 558 | 25075799 |
BE |
21 | 2 |
Vertigo, Product use issue, Intentional overdose, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 559 | 25075867 |
US |
65 | 2 |
Surgery, Product use issue, |
||||
SARILUMAB, |
||||
| 560 | 25075924 |
US |
60 | 2 |
Off label use, Product use issue, |
||||
TUCATINIB, TRASTUZUMAB, |
||||
| 561 | 25076009 |
US |
25 | |
Product use issue, |
||||
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, |
||||
| 562 | 25076066 |
US |
41 | 1 |
Product dose omission issue, Product use issue, No adverse event, Off label use, |
||||
ALECTINIB HYDROCHLORIDE, |
||||
| 563 | 25076089 |
US |
||
Product use issue, |
||||
ISTRADEFYLLINE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, NIFEDIPINE, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, ACETAMINOPHEN AND CODEINE, ALENDRONATE SODIUM, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, LORATADINE, LORATADINE ORAL, CARBIDOPA AND LEVODOPA, CLONAZEPAM, HYDROCHLOROTHIAZIDE, PREGABALIN, |
||||
| 564 | 25076234 |
US |
1 | |
Product use issue, |
||||
POLYETHYLENE GLYCOL 3350, |
||||
| 565 | 25076295 |
US |
21 | |
Pulmonary embolism, Product use issue, |
||||
TESTOSTERONE, TESTOSTERONE,, |
||||
| 566 | 25076572 |
US |
||
Product use issue, Wrong technique in product usage process, Cough, Device malfunction, |
||||
BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, |
||||
| 567 | 25076663 |
US |
70 | 1 |
Product use issue, |
||||
LENALIDOMIDE, |
||||
| 568 | 25076845 |
CN |
2 | 1 |
Pulmonary hypertension, Disease recurrence, Pneumonia, Hypoxia, Condition aggravated, Methaemoglobinaemia, Product use issue, |
||||
NITRIC OXIDE, NITRIC OXIDE, |
||||
| 569 | 25065972 |
US |
1 | |
Product use issue, |
||||
DOLUTEGRAVIR SODIUM AND RILPIVIRINE HYDROCHLORIDE, |
||||
| 570 | 25065984 |
US |
38 | 2 |
Dehydration, Decreased appetite, Impaired gastric emptying, Nausea, Product use issue, |
||||
SEMAGLUTIDE, TIRZEPATIDE, TIRZEPATIDE, GABAPENTIN, ALBUTEROL SULFATE, ALBUTEROL, OXYBUTYNIN, DIAZEPAM, DIAZEPAM ORAL, DIAZEPAM ORAL SOLUTION (CONCENTRATE), CYCLOBENZAPRINE, PANTOPRAZOLE, NALOXONE, METHYLPREDNISOLONE, PROMETHAZINE, PROMETHAZINE, PANCRELIPASE, FAMOTIDINE, LINACLOTIDE, ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, BENZONATATE, TIZANIDINE, MELOXICAM, AMLODIPINE, PREDNISONE, SEMAGLUTIDE, NAPROXEN, NAPROXEN SODIUM, |
||||
| 571 | 25066022 |
FR |
14 | 2 |
Hypogammaglobulinaemia, Product use issue, Off label use, |
||||
TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, RITUXIMAB, PREDNISONE, PREDNISONE, PREDNISONE, METHYLPREDNISOLONE, DARATUMUMAB, OBINUTUZUMAB, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 572 | 25066153 |
JP |
||
Product use issue, |
||||
MIRABEGRON, MIRABEGRON, SOLIFENACIN SUCCINATE, |
||||
| 573 | 25066375 |
CA |
2 | |
Abdominal discomfort, Alopecia, Contraindicated product administered, Maternal exposure during pregnancy, Glossodynia, Pain, Pemphigus, Product use issue, Rheumatoid arthritis, Systemic lupus erythematosus, |
||||
TOCILIZUMAB, RITUXIMAB, RITUXIMAB, TOCILIZUMAB, |
||||
| 574 | 25066385 |
US |
1 | |
Haemorrhage, Insurance issue, Product use issue, |
||||
| 575 | 25066458 |
CA |
1 | |
Auditory neuropathy spectrum disorder, Intentional product use issue, Product use issue, |
||||
SOMATROPIN, SOMATROPIN, |
||||
| 576 | 25066486 |
US |
2 | |
Ankylosing spondylitis, Hypertension, Contusion, Product distribution issue, Product use issue, |
||||
CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, |
||||
| 577 | 25066521 |
US |
||
Device issue, Device malfunction, Product use issue, Drug dose omission by device, |
||||
INFLIXIMAB-DYYB, |
||||
| 578 | 25066595 |
US |
1 | |
Recalled product administered, Product use issue, |
||||
ZOLPIDEM TARTRATE, |
||||
| 579 | 25066641 |
US |
57 | 1 |
Product use issue, |
||||
MAVACAMTEN, |
||||
| 580 | 25067296 |
US |
||
Dizziness, Product use issue, |
||||
RELUGOLIX, RELUGOLIX, |
||||
| 581 | 25067667 |
US |
70 | 1 |
Injection site urticaria, Injection site mass, Injection site bruising, Product use issue, |
||||
GLATIRAMER ACETATE, ATENOLOL, BACLOFEN, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, AMANTADINE, ALLOPURINOL, BENZONATATE, LOSARTAN, MONTELUKAST, PANTOPRAZOLE, METHOCARBAMOL, METHOCARBAMOL TABLETS, NABUMETONE, |
||||
| 582 | 25067779 |
CA |
43 | 2 |
Pulmonary fibrosis, Retinitis, Rheumatic fever, Exposure during pregnancy, Injury, Joint range of motion decreased, Infusion related reaction, Joint stiffness, Joint swelling, Joint dislocation, Intentional product use issue, Irritable bowel syndrome, Laryngitis, Live birth, Liver function test increased, Liver injury, Lower limb fracture, Lupus-like syndrome, Lupus vulgaris, Maternal exposure during pregnancy, Memory impairment, Mobility decreased, Muscle injury, Muscular weakness, Musculoskeletal stiffness, Nasopharyngitis, Nausea, Oedema, Oedema peripheral, Off label use, Osteoarthritis, Osteoporosis, Pain, Pain in extremity, Pemphigus, Pericarditis, Peripheral swelling, Pneumonia, Prescribed overdose, Prescribed underdose, Product use in unapproved indication, Product use issue, Pruritus, Psoriasis, Psoriatic arthropathy, Pyrexia, Rash, Red blood cell sedimentation rate increased, |
||||
DICLOFENAC SODIUM, DICLOFENAC SODIUM, DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, OXYCODONE, OXYCODONE, OXYCODONE, QUETIAPINE, QUETIAPINE EXTENDED-RELEASE, QUETIAPINE, QUETIAPINE EXTENDED-RELEASE, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, ERENUMAB-AOOE, RITUXIMAB, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, DICLOFENAC, DICLOFENAC SODIUM, DICLOFENAC, DICLOFENAC SODIUM, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, |
||||
| 583 | 25067877 |
US |
2 | |
Gallbladder disorder, Protein total decreased, Vomiting, Malaise, Intentional dose omission, Product use issue, |
||||
TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, HYDROXYCHLOROQUINE SULFATE, BUSPIRONE HYDROCHLORIDE, ATORVASTATIN CALCIUM, ACETAMINOPHEN, LEVOTHYROXINE SODIUM, PANTOPRAZOLE SODIUM, ERGOCALCIFEROL, MACITENTAN, CALCIUM, CARBAMAZEPINE, WARFARIN SODIUM, WARFARIN, |
||||
| 584 | 25067893 |
CA |
2 | |
Helicobacter infection, Lower limb fracture, Lupus vulgaris, Sleep disorder, Eye injury, Headache, Blood cholesterol increased, Confusional state, Abdominal pain upper, Infusion related reaction, Therapeutic response decreased, Pain, Drug ineffective, Vomiting, Psoriatic arthropathy, Anxiety, Glossodynia, Lower respiratory tract infection, Irritable bowel syndrome, Condition aggravated, Product use issue, Rheumatoid arthritis, Leukopenia, Contraindicated product administered, Sleep disorder due to general medical condition, insomnia type, Pericarditis, Fatigue, General physical health deterioration, Dizziness, Folliculitis, Anti-cyclic citrullinated peptide antibody positive, Type 2 diabetes mellitus, Road traffic accident, Deep vein thrombosis postoperative, Stomatitis, Urticaria, Hand deformity, Injury, Discomfort, Alopecia, Ulcer haemorrhage, Drug hypersensitivity, Maternal exposure during pregnancy, Synovitis, Impaired healing, Hypertension, Prescribed overdose, Gastrointestinal disorder, Product use in unapproved indication, Diarrhoea, Rash pruritic, Pemphigus, Peripheral swelling, Nasopharyngitis, Muscle injury, Intentional product use issue, Pyrexia, Systemic lupus erythematosus, Weight increased, Sinusitis, Gait inability, Duodenal ulcer perforation, Asthma, Chest pain, Off label use, Swelling, Autoimmune disorder, Fibromyalgia, Drug intolerance, Liver disorder, |
||||
NAPROXEN SODIUM, NAPROXEN SODIUM, COATED TABLETS, NAPROXEN SODIUM TABLET, COATED, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, HYDROXYCHLOROQUINE, TOFACITINIB, TOFACITINIB, OXYCODONE, LEFLUNOMIDE, ADALIMUMAB, ABATACEPT, ABATACEPT, TOCILIZUMAB, TOCILIZUMAB, ALENDRONATE SODIUM, PREDNISONE, PREDNISONE, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CALCIUM GLUCONATE, INFLIXIMAB, INFLIXIMAB, CHLORHEXIDINE GLUCONATE, ANTISEPTIC SKIN CLEANSER, CHLORHEXIDINE GLUCONATE, ANTISEPTIC SKIN CLEANSER, CHLORHEXIDINE GLUCONATE, ANTISEPTIC SKIN CLEANSER, LEFLUNOMIDE, CELECOXIB, CELECOXIB, CALCIUM CARBONATE, CALCIUM CHLORIDE INJECTION, CALCIUM CHLORIDE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, CERTOLIZUMAB PEGOL, VITAMIN C, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, USTEKINUMAB, MAGNESIUM, CAFFEINE, LORAZEPAM, ERGOCALCIFEROL, LORAZEPAM, LANSOPRAZOLE, LISINOPRIL, |
||||
| 585 | 25067902 |
US |
1 | |
Hallucination, Product use issue, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 586 | 25067948 |
US |
66 | 2 |
Product use issue, Product adhesion issue, |
||||
ESTRADIOL, |
||||
| 587 | 25068019 |
BE |
13 | 1 |
Malaise, Abdominal pain upper, Product use issue, Intentional overdose, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 588 | 25068024 |
US |
2 | |
Product use issue, Product adhesion issue, |
||||
ESTRADIOL, |
||||
| 589 | 25068035 |
BR |
1 | |
Dementia Alzheimer^s type, Condition aggravated, Product use issue, |
||||
RIVASTIGMINE, |
||||
| 590 | 25068192 |
US |
86 | 2 |
Product use issue, Product dose omission issue, |
||||
PIMAVANSERIN TARTRATE, PIMAVANSERIN TARTRATE, |
||||
| 591 | 25068401 |
48 | 1 | |
Ear infection, Product use issue, |
||||
UPADACITINIB, |
||||
| 592 | 25069111 |
US |
28 | 2 |
Dermatitis atopic, Product use issue, |
||||
DUPILUMAB, NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, SPIRONOLACTONE, |
||||
| 593 | 25069208 |
64 | 2 | |
Dizziness, Nausea, Product adhesion issue, Malaise, Asthenia, Circulatory collapse, Tremor, Dysstasia, Gait inability, Palpitations, Mydriasis, Vision blurred, Toxicity to various agents, Product use issue, |
||||
SCOPOLAMINE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 594 | 25069318 |
US |
50 | 2 |
Product use issue, |
||||
LENALIDOMIDE, GABAPENTIN, LOSARTAN POTASSIUM, LOSARTAN, SEMAGLUTIDE, ROSUVASTATIN CALCIUM, MIRTAZAPINE, APIXABAN, ERGOCALCIFEROL, |
||||
| 595 | 25069355 |
US |
77 | 2 |
Toxic epidermal necrolysis, Skin exfoliation, Product use issue, |
||||
REGORAFENIB, GLIMEPIRIDE, SITAGLIPTIN, LOSARTAN, APIXABAN, |
||||
| 596 | 25069420 |
US |
83 | 2 |
Visual impairment, Intentional product use issue, Off label use, Product use issue, |
||||
TUCATINIB, TUCATINIB, TRASTUZUMAB-ANNS, |
||||
| 597 | 25069644 |
BE |
13 | 2 |
Intentional self-injury, Product use issue, Intentional overdose, Pain, Vomiting, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 598 | 25069658 |
BE |
23 | 2 |
Hepatic failure, Product use issue, Intentional overdose, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 599 | 25069667 |
BE |
14 | 2 |
Abdominal pain, Product use issue, Intentional overdose, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 600 | 25069668 |
BE |
13 | 2 |
Vomiting, Intentional self-injury, Product use issue, Intentional overdose, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28